So for those currently dissatisfied with the capabilities of 1.5 T and 3 T MRI imaging technology, the US Food and Drug Administration has just approved a 7 T MRI device called a “Siemens Magnetom Terra”. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: 7-T, imaging, MRI | Leave a comment »
Dr. Zachary Klaassen and UroToday have provided us with four more interesting summaries of presentations by faculty at the European Association for Urology (EAU)’s meeting in Vienna last weekend. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biomarkers, care, focal, functional, genomics, imaging, molecular, patient-centered, therapy | 4 Comments »
Two recent papers by Sabouri et al. have suggested that a new MRI techique known as “luminal water imaging” may be able to improve the ability of MR scans to identify and grade prostate cancer prior to biopsy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, fraction, imaging, luminal, MRI, staging, water | 1 Comment »
A new paper in the Journal of Nuclear Medicine has reported the first use of [11C]sarcosine in combination with PET/CT scanning as a technique for imaging prostate cancer in man. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: carbon-11, imaging, PET/CT, sarcosine, scan | Leave a comment »
Our next CureTalks program will be on the evolving role of imaging in the diagnosis and management of prostate cancer on Thursday, July 27, at 5:00 p.m. Pacific / 8:00 p.m. Eastern time. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: CureTalk, imaging, Westphalen | Leave a comment »
As regular readers are well aware, there has for a while been an increase in the importance of new forms of high quality imaging studies in the diagnosis, work-up, and monitoring of men with prostate cancer (localized, locally advanced, and advanced). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: director, imaging, prostate | 1 Comment »
Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …
Filed under: Living with Prostate Cancer, Uncategorized | Tagged: Axumin, imaging, PET, scan, [18F]fluciclovine | 4 Comments »
